Frontiers in CNS Therapeutic Development: Breaching the Blood-Brain Barrier

The blood-brain barrier (BBB) presents a significant challenge in developing effective treatments for central nervous system disorders. Various approaches are being explored to overcome this pharmacological challenge, including shuttle technologies, viral vectors, non-viral delivery particles, intranasal distribution, and devices for direct delivery to the CNS.

Biopharma companies and investors have shown significant interest in BBB technologies, with 63 strategic transactions (licensing/acquisitions) over the past six years and USD2.5bn raised in total from venture financing between 2019 and 2023. 

The DNB//Back Bay Partnership analyzed the clinical development landscape, recent transactions, and financing activity to better understand which technologies are advancing to the clinic and gaining traction.

 Download FRONTIERS IN CNS THERAPEUTIC DEVELOPMENT 

 Learn about DNB//Back Bay and read our disclosures: www.bblsa.com/dnbback-bay